Avita Medical Inc Stock Price, News & Analysis

AVITA Medical (NASDAQ: RCEL) announced that hospitals will now be eligible for New Technology Add-on Payment (NTAP) reimbursement from CMS when using RECELL to treat non-burn trauma and surgical full-thickness wounds. Starting October 1, 2025, hospitals can receive up to $4,875 in additional reimbursement per case through September 30, 2026.

The NTAP designation was granted under CMS's alternative pathway for FDA Breakthrough Devices. A clinical trial published in the Journal of Trauma and Acute Care Surgery demonstrated that RECELL achieved comparable wound closure while requiring 27% less donor skin compared to standard skin grafting. The technology prepares Spray-On Skin™ cells from a small sample of the patient's healthy skin.

AVITA Medical (NASDAQ: RCEL) has received CE Mark approval under the EU Medical Device Regulation for RECELL GO, enabling commercialization across Europe and other markets that recognize the CE Mark. RECELL GO is a point-of-care device that prepares Spray-On Skin™ Cells from a patient's own skin sample to promote healing in burns and traumatic or surgical wounds.

Recent data presented at the 2025 European Burns Association Congress showed that adults with deep partial-thickness burns treated with RECELL experienced a 36% reduction in hospital stays compared to traditional grafting. The company plans to begin commercialization in select European countries, including Germany, Italy, and the United Kingdom.

AVITA Medical (NASDAQ: RCEL) announced compelling real-world data demonstrating significant benefits of its RECELL® System in burn treatment. The analysis from the U.S. national burn registry showed that RECELL reduces hospital length of stay by 36% compared to traditional skin grafts in adults with deep second-degree burns.

The study of 741 adults revealed RECELL-treated patients experienced an average 5.6-day reduction in hospital stay, potentially saving over $42,000 per patient in costs. The system enables hospitals to treat 13 more patients per bed annually. RECELL requires 97.5% less skin compared to traditional grafts while improving donor site healing, pain, and scarring.

AVITA Medical (NASDAQ: RCEL) has announced its participation in three major investor conferences this September. The company's management will engage in the following events:

• Cantor Global Healthcare Conference on September 4, featuring a fireside chat with CFO David O'Toole
• Morgan Stanley Global Healthcare Conference on September 8, with CEO Jim Corbett
• Lake Street Capital Markets Best Ideas Growth Conference on September 11, with CFO David O'Toole

The Morgan Stanley fireside chat will be available via webcast for 90 days on AVITA Medical's investor relations website.

AVITA Medical (NASDAQ: RCEL) has successfully completed a private placement in Australia, raising approximately US$15 million (A$23 million) through the issuance of 17.2 million new CHESS Depositary Interests (CDIs). The placement was priced at A$1.32 per CDI, representing an 11% discount to the last closing price of A$1.48.

The funds will be utilized for working capital requirements and strategic flexibility to support the company's therapeutic acute wound portfolio growth. AVITA Medical expects this capital to sustain operations until it achieves free cash flow in 2026. The new CDIs are scheduled for settlement on August 19, 2025, with trading on the ASX commencing August 20, 2025.

AVITA Medical (NASDAQ: RCEL) has announced an upcoming investor webinar briefing scheduled for August 14, 2025, at 9 AM AEDT (August 13 at 4 PM PST). The presentation will feature CEO Jim Corbett and CFO David O'Toole, who will discuss the company's Q2 2025 financial and business results.

The webinar will include a Q&A session, with participants able to submit questions through the registration page. A replay will be made available on AVITA Medical's investor relations website after the event.

AVITA Medical (NASDAQ: RCEL) reported Q2 2025 financial results with commercial revenue of $18.4 million, up 21% year-over-year, despite facing significant headwinds. The company reported a net loss of $9.9 million ($0.38 per share), an improvement from $15.4 million loss in Q2 2024.

Key developments include Medicare Administrative Contractor (MAC) payment delays affecting RECELL® System demand, leading to revised full-year 2025 revenue guidance of $76-81 million, down from $100-106 million. The company amended credit terms with OrbiMed, lowering revenue covenants and issuing stock instead of cash payment.

Clinical highlights show RECELL reducing hospital stays by 36%, and CMS approval of New Technology Add-on Payment for trauma wounds. The company now expects to reach cash flow break-even in Q2 2026 and GAAP profitability in Q3 2026.

AVITA Medical (NASDAQ: RCEL) has announced significant changes to its Board of Directors. Dr. Michael Tarnoff, MD, FACS has been appointed as a non-executive Director effective August 6, 2025, bringing extensive executive and medical leadership experience from Tufts Medical Center and Medtronic.

Additionally, the company announced a leadership transition where Cary Vance will succeed Lou Panaccio as Board Chair effective August 7, 2025. Panaccio steps down after more than 10 years of service. The changes come as AVITA Medical strengthens its focus on advancing patient-centric wound-healing technologies and expanding its presence across healthcare settings.

AVITA Medical (NASDAQ: RCEL) has scheduled its second quarter 2025 financial results announcement for Thursday, August 7, 2025, after U.S. market close. The company will host a conference call and webcast on the same day at 1:30 p.m. Pacific Time (August 8, 2025, at 6:30 a.m. Australian Eastern Standard Time).

Investors can access the live webcast through the Events & Presentations section on AVITA Medical's website. To join via telephone, participants must pre-register to receive dial-in details and a personal PIN. A replay will be available on the company's Investor Relations website after the event.